In monitoring patients for drug-induced hearing loss, most audiometric evaluations are limited to the range of frequencies from 0.25 to 8 kHz. However, such testing would fail to detect ototoxicity in patients who have already experienced hearing loss in the ultrahigh frequencies from 10 to 20 kHz. Awareness of ultrahigh-frequency ototoxicity could lead to changes in a drug regimen to prevent further damage. We conducted a prospective study of 105 patients who were receiving a potentially ototoxic drug-either gentamicin, amikacin, or cisplatin-to assess the value of ultrahigh-frequency audiometry in detecting systemic drug-induced hearing loss. We found that expanding audiometry into the ultrahigh-frequency range led to the detection of a substantial number of cases of hearing loss that would have otherwise been missed.
Introduction
Although the treatment and rehabilitation of hearing loss have reached highly sophisticated levels, technical advances have their drawbacks, as well, as two of the causes of deafness-ototoxic drugs and noise-are products of our mechanized and advanced society. 1, 2 Hearing loss secondary to both of these causes has been shown to typically begin in the higher frequencies that correspond with the basal end of the cochlea. [3] [4] [5] Most hearing evaluations performed as part of ototoxicity monitoring are limited to audiometric testing in the frequencies from 0.25 to 8 kHz. 1, 3, [6] [7] [8] [9] [10] [11] [12] [13] However, by the time hearing loss is detected with these conventional methods, hearing damage has already occurred. Fortunately, this may be preventable. Identifi cation of initial hearing loss in the ultrahigh frequencies from 10 to 20 kHz would provide the earliest possible warning that preventive and corrective measures should be instituted before the loss encroaches upon the speech frequencies.
In the absence of standardized guidelines for monitoring ototoxicity, we undertook a study to investigate the effi cacy of including ultrahigh-frequency audiometry as part of ototoxicity monitoring.
Patients and methods
Our study population was drawn from among all patients seen in the Department of Otorhinolaryngology at the Himalayan Institute of Medical Sciences in northern India over an 18-month period. Our inclusion criteria required that study subjects be postoperative patients or seriously ill patients treated with an aminoglycoside (gentamicin or amikacin) or cisplatin. Exclusion criteria included a tympanic membrane perforation, serous otitis media, or chronic suppurative otitis media.
Aft er providing informed consent, all patients provided a relevant history and underwent an ear examination. Otoscopy was performed to visually confi rm that the ear canal and tympanic membrane were normal. Patients with presbycusis were included in the study. A total of 105 patients-68 males and 37 females, aged 13 to 65 years (mean 39)-met our eligibility criteria. Of these, 70 were treated with gentamicin, 15 with amikacin, and 20 with cisplatin.
Prior to exposure to aminoglycoside or cisplatin therapy, all patients underwent baseline pure-tone audiometry in the range of frequencies from 0.25 to 20 kHz. Th e same testing was administered again right aft er exposure and again 1 month later. All audiometric tests were conducted in a double-walled, sound-attenuated room with an Interacoustics AC40 audiometer. TDH-39 headphones were used for the low frequencies and Koss Pro headphones for the high frequencies.
Volume 90, Number 5 www.entjournal.com ■ 219
THE ROLE OF ULTRAHIGH-FREQUENCY AUDIOMETRY IN THE EARLY DETECTION OF SYSTEMIC DRUG-INDUCED HEARING LOSS

Discussion
In our study, systemic drug-related hearing loss was detected in 41.4% of the gentamicin patients, in 40.0% of the amikacin patients, and in 50.0% of the cisplatin patients.
In most of the patients in the oldest group (51 to 70 yr), no response was noted at the higher frequencies (18 and 20 kHz), both before and aft er drug exposure, because of presbycusis. Th erefore, it was diffi cult to detect hearing loss at these frequencies. Most of the cisplatin recipients were in the oldest age group.
Among the 45 patients aff ected by ototoxicity, hearing loss was unilateral in 14 patients (31.1%). Th is suggests that serial audiometry at ultrahigh frequencies might detect ototoxicity before it becomes bilateral. If so, the patient's drug regimen can be altered to prevent progression to bilaterality.
Among the gentamicin patients, hearing loss was most common in all the frequencies between 10 and 20 kHz. In the amikacin patients, hearing loss was most common at 10, 12, and 18 kHz, and in the cisplatin patients, the most aff ected frequencies were 8, 10, 14, and 16 kHz (table) .
Th e present study shows that if we had limited ototoxicity monitoring to frequencies no higher than 8 kHz, we would have missed hearing loss in an appreciably high percentage of patients. Also, we believe that our ototoxicity detection rate with ultrahigh-frequency monitoring should have been even higher among the younger patients because of the likelihood that their high-frequency hearing was intact at baseline. Age was also a factor in our low ototoxicity detection rate at 18 and 20 kHz in the cisplatin patients; the low rate was probably attributable to the fact that these patients were considerably older than the other patients in the study group and that they already had some age-related hearing loss. Detection of hearing loss at the ultrahigh frequencies was much higher in the gentamicin pa-
Results
At the fi rst post-treatment audiometric assessment, hearing loss was detected in 45 of the 105 patients (42.9%). Deafness was present in 29 of the 70 gentamicin patients (41.4%), in 6 of the 15 amikacin patients (40.0%), and in 10 of the 20 cisplatin patients (50.0%).
Sex. Hearing loss was detected in 42 of the 68 males (61.8%) and in 14 of the 37 females (37.8%).
Age. Patients in each treatment category were further stratifi ed into three subgroups based on age: 10 to 30 years, 31 to 50 years, and 51 to 70 years. In the 29 gentamicin patients with hearing loss, 15 (51.7%) were aged 10 to 30 years, 10 (34.5%) were aged 31 to 50 years, and 4 (13.8%) were aged 51 to 70 years. Th e corresponding fi gures in the amikacin patients were 3 (50.0%), 2 (33.3%), and 1 (16.7%), and the respective fi gures in the cisplatin patients were 0, 4 (40.0%), and 6 (60.0%).
Laterality. Of the 45 cases of hearing loss, 31 (68.9%) were bilateral and 14 (31.1%) were unilateral, for a total of 76 ears. Among the gentamicin cases, 20 were bilateral and 9 were unilateral, for a total of 49 ears. Among the amikacin cases, 3 were bilateral and 3 were unilateral, for a total of 9 ears. Finally, of the cisplatin cases, 8 were bilateral and 2 cases were unilateral, for a total of 18 ears.
Frequencies related to hearing loss. Hearing loss involved more than one frequency in some cases; in all, 97 frequencies were involved (table). Hearing loss was much more common in the 10-to 20-kHz range (70.1%) than in the 0.25-to 8.0-kHz range (29.9%). Th e percentages of aff ected high/low frequencies were 68.6/31.4% in the gentamicin cases, 76.9/23.1% in the amikacin cases, and 71.4/28.6% in the cisplatin cases.
Reversal of hearing loss. At the second post-treatment audiometry, a reversal of hearing loss was seen in 3 of the 29 gentamicin patients (10.3%), 1 of the 6 amikacin patients (16.7%), and 1 of the 10 cisplatin patients (10.0%). While amyloidosis has been considered to be an idiopathic disease, increasing evidence points to an immunocyte-derived etiology. Two theories have been suggested for the immunogenic origin of amyloid. Th e fi rst suggests a plasma cell immunoglobulin response to inhaled antigens, and the second suggests an inability to clear excessive or abnormal immunoglobulins produced by monoclonal lymphoid tissue. 6 Localized amyloidosis is usually associated with the AL type of amyloid. AL-type amyloidosis can occur alone and it can be associated with lymphoproliferative disorders such as multiple myeloma or Waldenström macroglobulinemia. In our patient, immunoglobulin light-chain immunohistochemistry was negative, as was fl ow cytometry. Instead, pathology identifi ed nodular amyloidosis, which is associated with the AA type of amyloid. 6 Th is type of amyloid has been associated with underlying chronic infl ammation, and it may complicate other disorders, including rheumatoid arthritis and periodic fever syndromes.
In the upper aerodigestive tract, two types of infi ltration occur: diff use subepithelial infi ltration and tumor nodule infi ltration. Amyloid tumor nodules occur more commonly in the nasopharynx and larynx, while subepithelial infi ltration predominates elsewhere. 6 To the best of our knowledge, only 10 cases of localized oropharyngeal amyloidosis have been previously reported since 1933. [6] [7] [8] [9] Among these cases, 5 included the presence of amyloid plaques within the tonsil, and the other 5 involved localized tumor-like deposits called amyloidomas that emanated from the tonsil. As is evident in fi gure 1, the lesion in our patient appeared to arise from the posterolateral oropharyngeal wall, from whence it grew anteriorly into the tonsillar fossa.
While amyloidosis of the upper aerodigestive tract is typically a localized lesion, it is considered prudent to work up the patient for systemic involvement. In our patient, urine and serologic evaluations, as well as chest x-ray, revealed no evidence of systemic disease.
Th e standard treatment for localized amyloid lesions of the upper aerodigestive tract is surgical resection. Recurrence is not uncommon, and multiple surgeries may be required. 6 Our patient exhibited no evidence of recurrence 24 months out from surgery. tients, who were considerably younger.
We conclude that the inclusion of ultrahigh frequencies in ototoxicity-monitoring audiometry is more useful than low-frequency audiometry alone in detecting early, preventable drug-induced hearing loss.
